Voyager Therapeutics (VYGR) Expected to Release Earnings on Monday

Key Points

• Voyager Therapeutics is expected to report Q3 2026 earnings on Monday, November 9. Analysts forecast a loss of $0.41 per share and revenue of $6.35 million; the earnings call is scheduled for November 13 at 4:00 p.m. ET.
• In its previous quarter, Voyager reported a loss of $0.40 per share, beating estimates for a $0.48 loss, but revenue of $3.17 million fell short of the $4.52 million forecast.
• The stock recently opened at $1.72, near its 52-week low of $1.68. Despite mixed analyst opinions, Voyager has a “Moderate Buy” consensus rating and a consensus price target of $16.50.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) is expected to be issuing its Q3 2026 resultson Monday, November 9th. Analysts expect Voyager Therapeutics to post earnings of ($0.41) per share and revenue of $6.35 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The firm had revenue of $3.17 million for the quarter, compared to analysts' expectations of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. On average, analysts expect Voyager Therapeutics to post ($1.63) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $1.72 on Monday. The firm has a market cap of $105.98 million, a P/E ratio of -0.96 and a beta of 1.28. Voyager Therapeutics has a fifty-two week low of $1.68 and a fifty-two week high of $5.48. The firm has a 50-day simple moving average of $2.71 and a two-hundred day simple moving average of $3.46.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VYGR. HC Wainwright reaffirmed a "buy" rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Voyager Therapeutics in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager's research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.